Elanco Animal Health Inc (5EA.DE) Q2 2025 Earnings Report

Elanco Animal Health reported Q2 2025 revenue of $1.241 billion, up 4.81% year over year and 4.02% quarter over quarter, underscoring resilient demand across its Companion Animal and Food Animal portfolios. Despite top-line growth, profitability showed pressure: gross profit was $577 million with a gross margin of 46.5%, and operating income totaled $85 million (operating margin ~6.85%), while EBITDA stood at $264 million (EBITDA margin ~21.27%). Net income was $11 million, producing a net margin of 0.89% for the quarter, as negative items such as total other income/expenses net (-$60 million) weighed on pre-tax income. Interest expense was $70 million and depreciation & amortization were $169 million, contributing to a pre-tax income of $25 million and after taxes a net income of $11 million. Earnings per share (diluted) were $0.022. The quarter reflects meaningful revenue momentum but ongoing margin headwinds and non-operating charges that temper net profitability. Management commentary is not included in the provided data, so the assessment focuses on the reported metrics and historical quarterly context. Investors should monitor gross margin stabilization, cost controls, and the contribution of niche growth initiatives (vaccines, parasite control, and nutrition) to sustain profitability as the company scales its animal health portfolio.